Advertisement

Immunity

  • Shawn Babiuk
Chapter

Abstract

There are many factors that can play a role in the susceptibility of infection to lumpy skin disease virus (LSDV). The interaction between the host’s immune system and the virus determines the outcome. Following natural or experimental infection of cattle with virulent LSDV, virus neutralizing antibodies are elicited. These antibodies are detected starting around 15 days following infection, with the titres of the antibodies increasing over the next 2 weeks and then wane. With capripoxvirus infections, mild infections generate lower antibody responses compared to severe infections (Bowden et al. 2009). Unfortunately, following vaccination with several of the currently available vaccines, in many times only low or undetectable levels of virus neutralizing antibodies are elicited.

References

  1. Amara RR, Nigam P, Sharma S, Liu J, Bostik V (2004) Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78:3811–3816CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bowden TR, Coupar BE, Babiuk SL, White JR, Boyd V, Duch CJ, Shiell BJ, Ueda N, Parkyn GR, Copps JS, Boyle DB (2009) Detection of antibodies specific for sheeppox and goatpox viruses using recombinant capripoxvirus antigens in an indirect enzyme-linked immunosorbent assay. J Virol Methods 161:19–29CrossRefPubMedGoogle Scholar
  3. Bray M, Wright ME (2003) Progressive vaccinia. Clin Infect Dis 36:766–774CrossRefPubMedGoogle Scholar
  4. Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G (2006) Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 80:6339–6344CrossRefPubMedPubMedCentralGoogle Scholar
  5. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R (2003) Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969–4973CrossRefPubMedGoogle Scholar
  6. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11:740–747CrossRefPubMedGoogle Scholar
  7. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L (1999) Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71–80CrossRefPubMedGoogle Scholar
  8. Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, Zheng M, Erickson JJ, Boyd KL, McAfee KJ, Oseroff C, Hadrup SR, Bennink JR, Hildebrand W, Edwards KM, Crowe JE Jr, Williams JV, Buus S, Sette A, Schumacher TN, Link AJ, Joyce S (2013) Discovering naturally processed antigenic determinants that confer protective T cell immunity. J Clin Invest 123:1976–1987CrossRefPubMedGoogle Scholar
  9. Gordon J, Mohandas A, Wilton S, Dales S (1991) A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology 181:671–686CrossRefPubMedGoogle Scholar
  10. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9:1131–1137CrossRefPubMedGoogle Scholar
  11. Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CH (1965) Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children: probable human runt disease. N Engl J Med 273:953–958CrossRefPubMedGoogle Scholar
  12. Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G (2006) Subunit recombinant vaccine protects against monkeypox. J Immunol 177:2552–2564CrossRefPubMedGoogle Scholar
  13. Hooper JW, Custer DM, Thompson E (2003) Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306:181–195CrossRefPubMedGoogle Scholar
  14. Hsiao JC, Chung CS, Chang W (1999) Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 73:8750–8761PubMedPubMedCentralGoogle Scholar
  15. Kitching RP (1986) Passive protection of sheep against capripoxvirus. Res Vet Sci 41:247–250PubMedCrossRefGoogle Scholar
  16. Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS (2009) In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 27:6471–6479CrossRefPubMedPubMedCentralGoogle Scholar
  17. Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M, Ennis F, Terajima M, Sutter G, Crotty S, Drexler I, Franchini G, Yewdell JW, Head SR, Blum J, Peters B, Sette A (2010) Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol 5:221–239CrossRefPubMedPubMedCentralGoogle Scholar
  18. Ngichabe CK, Wamwayi HM, Ndungu EK, Mirangi PK, Bostock CJ, Black DN, Barrett T (2002) Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiol Infect 128:343–349CrossRefPubMedPubMedCentralGoogle Scholar
  19. Panchanathan V, Chaudhri G, Karupiah G (2006) Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 80:6333–6338CrossRefPubMedPubMedCentralGoogle Scholar
  20. Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM (2007) Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 81:4070–4079CrossRefPubMedPubMedCentralGoogle Scholar
  21. Perrin LH, Zinkernagel RM, Oldstone MB (1977) Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J Exp Med 146:949–969CrossRefPubMedPubMedCentralGoogle Scholar
  22. Rodriguez JF, Janeczko R, Esteban M (1985) Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol 56:482–488PubMedPubMedCentralGoogle Scholar
  23. Sette A, Grey H, Oseroff C, Peters B, Moutaftsi M, Crotty S, Assarsson E, Greenbaum J, Kim Y, Kolla R, Tscharke D, Koelle D, Johnson RP, Blum J, Head S, Sidney J (2009) Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27(Suppl 6):G21–G26CrossRefPubMedPubMedCentralGoogle Scholar
  24. Weiss KE (1968) Lumpy skin disease virus. Virol Monogr 3:111–131CrossRefGoogle Scholar
  25. Wolffe EJ, Vijaya S, Moss B (1995) A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211:53–63CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Shawn Babiuk
    • 1
    • 2
  1. 1.Canadian Food Inspection Agency, National Centre for Foreign Animal DiseaseWinnipegCanada
  2. 2.University of ManitobaWinnipegCanada

Personalised recommendations